Bristol-Myers Squibb has a long history of collaborations with scientific and commercial partners, dating back to the 1980’s. We, together with our partners, have developed some of the most successful products in their respective therapeutic areas. In the early years, we began by building collaborations into flagship brands with Sankyo (Pravachol, 1985), Yale University (Zerit, 1987), National Cancer Institute (Taxol, 1991), Sanofi (Plavix and Avapro, 1993), Lipha (Glucophage, 1994), and Otsuka (Abilify, 1999).
Today, we continue to leverage our collaborative workstyle in alliances on innovative medicines that address high unmet medical needs.
Below is a sample listing of our recent collaborations which provide both great scientific and commercial value, and current or potential treatments for the patients we serve.
In June 2013, Bristol-Myers Squibb and Simcere
announced a collaboration in China on the development and commercialization of the subcutaneous (SC) formulation of Bristol-Myers Squibb’s biologic medicine, ORENCIA® (abatacept), for the treatment of rheumatoid arthritis.
In May 2013, Bristol-Myers Squibb and Ambrx
announced a collaboration for the discovery and development of novel antibody drug conjugates using Ambrx's protein medicinal chemistry technology.
In February 2013, Bristol-Myers Squibb and Reckitt Benckiser
announced a three-year collaboration agreement for several of Bristol-Myers Squibbs’ over-the-counter medicines currently sold across Latin America, primarily in Mexico and Brazil.
In December 2012, Bristol-Myers Squibb and The Medicines Company
announced a global alliance to license and collaborate on Recothrom®, a recombinant thrombin approved by the U.S. Food and Drug Administration for use as a topical hemostat to control non-arterial bleeding during surgical procedures.
In September 2012, Bristol-Myers Squibb and Vanderbilt University
announced a collaboration for the discovery, development and commercialization of novel therapies acting on the mGluR4 glutamate receptor, known as positive allosteric modulators or PAMs, for the treatment of Parkinson’s disease.
In September 2012, Bristol-Myers Squibb and nine other leading biopharmaceutical companies
announced the formation of a non-profit organization to accelerate the development of new medicines. Abbott, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Johnson & Johnson, Pfizer, Genentech, a member of the Roche Group, and Sanofi.
In May 2012, Bristol-Myers Squibb and Tsinghua University
announced the formation of a multi-year strategic partnership in which Bristol-Myers Squibb will fund research efforts at Tsinghua University’s School of Life Sciences to identify and validate novel targets in oncology and immunoscience.
In May 2012, Bristol-Myers Squibb announced the formation of the International Immuno-Oncology Network (II-ON), a global collaboration between industry and academia that aims to further the scientific understanding of immuno-oncology. In addition to Bristol-Myers Squibb, the II-ON is currently comprised of the following ten leading cancer-research institutions: Clinica Universidad Navarra, Pamplona, Spain, Dana-Farber Cancer Institute, Boston, MA, The Earle A. Chiles Research Institute (Providence Health & Services), Portland, OR , Institut Gustave Roussy, Villejuif, France , Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione G. Pascale,” Naples, Italy, Johns Hopkins Kimmel Cancer Center, Baltimore MD , Memorial Sloan-Kettering Cancer Center, New York, NY, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, UK, The Netherlands Cancer Institute, Amsterdam, NL, The University of Chicago, Chicago, IL.
In February 2012, Bristol-Myers Squibb and Duke Translational Medicine Institute (DTMI)
announced the formation of a strategic relationship which builds on a decade of collaboration in cardiology, endocrinology, and oncology, and will extend into other therapeutic areas at all stages of development, fostering increased exchange between DTMI researchers, and Bristol-Myers Squibb scientists and project teams.
In December 2011, Bristol-Myers Squibb and Tibotec Pharmaceuticals
, one of the Janssen Pharmaceutical Companies, announced a clinical collaboration to evaluate the utility of daclatasvir (BMS-790052), Bristol-Myers Squibb’s investigational NS5A replication complex inhibitor, in combination with Tibotec Pharmaceuticals’ investigational NS3 protease inhibitor, TMC435, for the treatment of chronic hepatitis C virus (HCV).
Bristol-Myers Squibb and Allergan, Inc. announced a global agreement for the development and commercialization of an oral medication for the treatment of neuropathic pain.
We entered into a global collaboration with Nissan Chemical Industries, Ltd. and Teijin Pharma Limited for the development and commercialization of NTC-801, a selective inhibitor of the acetylcholine-activated potassium ion channel (IKACh) for the maintenance of normal sinus rhythm in patients with atrial fibrillation.
Bristol-Myers Squibb entered into a global collaboration with ZmyoGenetics of Seattle, Washington to develop and commercialize PEG-Interferon lambda, a new treatment for hepatitis C. ZymoGenetics was subsequently acquired by Bristol-Myers Squibb in 2010.
Bristol-Myers Squibb entered into a development/commercialization agreement with KAI Pharmaceuticals for a cardiovascular disease therapy.
Bristol-Myers Squibb entered into an agreement with PDL BioPharma of California to develop and globally commercialize a therapy for multiple myeloma.
Worldwide co-development and co-promotion agreement for the Bristol-Myers Squibb - discovered apixaban, a Factor Xa inhibitor for thrombosis.
In Sept 2007, Bristol-Myers Squibb Company (NYSE: BMY) acquired privately held Adnexus Therapeutics, developer of a new therapeutic class of biologics called Adnectins™. The acquisition of Adnexus will help advance Bristol-Myers Squibb's biologics strategy across multiple therapeutic areas and includes a Phase I oncology biologic, Angiocept™. Adnexus Therapeutics will become a subsidiary of Bristol-Myers Squibb and remain based in Waltham, Massachusetts.
Co-development and co-promotion agreement for ONGLYZA™ (saxagliptin),
approved by the FDA for the treatment of type 2 diabetes in adults, and dapagliflozin, an investigational compound for the treatment of type 2 diabetes.
Agreement to identify triple re-uptake inhibitors for clinical development for depression and other CNS diseases; led to additional research collaboration screening Albany’s natural products library against multiple targets looking for novel hit compounds
Agreement to screen selected lead compounds against targets in Ambit’s KinomeScan panel of kinases; relationship extended and expanded twice to include all lead compounds and all compounds in Bristol-Myers Squibbs' kinase-specific compound library.